BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ECI830 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ECI830\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06726148-9116@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:ECI830: Phase 1/2 readout est. (NCT06726148)
DESCRIPTION:ECI830\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : Study of ECI830 Single Agent or in Combination in Patients With Advanced
  HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors\
 nEstimated primary completion: 25 September 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/eci830#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06726148
URL:https://assetmemo.bio/drug/eci830#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
